Published in Vaccine Weekly, May 28th, 2008
"Murine erbB2 models a clinically relevant tumor-associated self-antigen; its human homolog ( HER-2/neu) is overexpressed in breast cancer and in 80% of metastatic prostate cancers. Following one infection, similar to 47% of DCs overexpressed erbB2tr. To determine whether low doses of transduced DCs could protect mice from prostate cancer cells, we performed prime/boost...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly